Tech Company Financing Transactions
Ferrosa Therapeutics Funding Round
Ferrosa Therapeutics, based in Basel, secured $3.5 million from Forty51 Ventures and private investors.
Transaction Overview
Company Name
Announced On
4/23/2026
Transaction Type
Venture Equity
Amount
$3,500,000
Round
Seed
Investors
Forty51 Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance its preclinical program through antibody generation, bispecific engineering, and in vivo proof-of-concept studies in disease-relevant animal models.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Basel, Undisclosed
Switzerland
Basel, Undisclosed
Switzerland
Phone
Undisclosed
Website
Email Address
Overview
We are developing next-generation biologics to address anemia of inflammation, an underserved condition affecting millions of patients with chronic kidney disease (CKD), cancer, and autoimmune disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Martin Stern
Co-Founder
Sascha Bucher
Co-Founder
Sara Nunez-Garcia
Browse more venture capital transactions:
Prev: 4/23/2026: PvX Partners venture capital transaction
Next: 4/23/2026: Copperhelm venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to record funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs